News & Videos - ITAMAR MEDICAL LTD. ITMMF

CAESAREA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that it will report its unaudited financial results for the third quarter of 2019 before the U.S. market opens on Tuesday,...

- CMS Announces 2020 Fee Schedule - CAESAREA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, today announced that Blue Shield of California (BSC) and the Blue Cross Blue Shield Federal Employee Plan...

CAESAREA, Israel, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced the appointment of Jennifer Cook, MD, FAHA, FACC to the newly created position of Global Medical Director, effective immediately. In...

CAESAREA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will present at the Ladenburg Thalmann 2019...

- Total Second Quarter Revenues Increase 21% to $7.4 Million - - WatchPAT TM Revenues Increase 16% in the Second Quarter to $6.5 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today reported unaudited financial results for...

CAESAREA, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will report its unaudited financial results for the second quarter of 2019 before the U.S. market opens on Wednesday, August 14, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel...

New system expands WatchPAT access to additional sleep centers by reducing infrastructure needs and eliminating capital requirements; also reduces infection risk for in-patient sleep apnea testing CAESAREA, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq:ITMR) (TASE:ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that it has received 510(k) clearance from...

Collaboration designed to integrate sleep apnea management into cardiology care pathways CAESAREA, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality...

Collaboration designed to integrate sleep apnea management into cardiology care pathways CAESAREA, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality...

- WatchPAT™ Revenues Increase 15% to $5.8 Million - - U.S. WatchPAT Revenues Increase 34% to $4.3 Million - - Total Revenues Increase 11% to $6.1 Million - CAESAREA, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today reported unaudited financial results for the first quarter of 2019. “We are pleased that the...

Latest WatchPAT innovation improves patient comfort and simplifies physician workflow WatchPAT 300 utilizes peripheral arterial tone and other signals to calculate True Sleep Time and Complete Sleep Architecture to accurately and reliably diagnose both obstructive and central sleep apnea. CAESAREA, Israel, March 20, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a...

Full Year 2018 Revenues Increased 17 % to $24.2 Million ; WatchPAT™ Revenues Increased 24% to $22.4 Million Fourth Quarter 2018 Revenues Increased 9% to $6.6 Million ; WatchPAT Revenues Increased 19% to $6.0 Million American Depositary Shares (ADSs) Commenced Trading on Nasdaq Under the Ticker Symbol "ITMR" on February 27, 2019 CAESAREA, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive...

CAESAREA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that Gilad Glick, Chief Executive Officer of Itamar Medical, will present at the Oppenheimer 29 th Annual Healthcare Conference in New York on March 20, 2019 at 3:20 PM ET. A live and archived webcast of the presentation...

Will Trade on both Nasdaq and TASE under the Ticker Symbol ‘ITMR’ CAESAREA, Israel, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will list and trade its American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol “ITMR” on or about February...

Selection as one of the most prominent and important articles of 2018 reflects significant contribution to advancing cardiovascular health CAESAREA, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that an article previously published in Circulation 1 has been selected for inclusion in the journal’s 2018...

CAESAREA, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a medical technology company that designs, develops, manufactures and sells sleep apnea diagnostic ambulatory products and related services, today announced a digital education partnership with CardioVisual to educate cardiovascular patients and physicians on the importance of diagnosing and treating sleep apnea to improve patient outcomes and streamline cardiology practice workflow. Obstructive sleep apnea has...

CAESAREA, Israel, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that it has entered into definitive agreements for a $11.5 million private placement at a purchase price of NIS 1.1693 per ordinary share of the Company, or $9.55 per American Depositary Share (ADSs), each representing 30 ordinary shares. Of the $11.5...

Third Quarter 2018 Highlights: Achieved 14.7% increase in third-quarter revenue to a record $6.1 million U.S. revenues increased 29% compared with third quarter 2017 Gross profit remained strong at 74.3% of total revenues Cash basis (non IFRS) operating loss of $0.3 million CAESAREA, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Itamar Medical (TASE: ITMR ), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology...

CAESAREA, Israel, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea with a focus on the cardiology market, today announced the release of the 2019 Fee Schedule from the U.S. Centers for Medicare & Medicaid Services (CMS) that should support broad use of its WatchPAT technology. WatchPAT is the only product in the market today that uses Peripheral Arterial Tone (PAT)...

Second Quarter 2018 Highlights: Achieved 20% increase in revenue to a record $6 million Recurring revenue represents 67% of revenue in North America Maintained gross profit of 76% of total revenue Cash basis (non IFRS) operating loss of $0.4 million Board of Directors approved level II American Depositary Receipt (ADR) CAESAREA, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices...